Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures.
COVID-19
Newcastle Disease Virus
SARS-CoV-2
Vero suspension culture
bioreactor production
vaccine production platform
viral vaccine bioprocess
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
16 Nov 2021
16 Nov 2021
Historique:
received:
19
10
2021
revised:
11
11
2021
accepted:
12
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
The ongoing COVID-19 pandemic drew global attention to infectious diseases, attracting numerous resources for development of pandemic preparedness plans and vaccine platforms-technologies with robust manufacturing processes that can quickly be pivoted to target emerging diseases. Newcastle Disease Virus (NDV) has been studied as a viral vector for human and veterinary vaccines, but its production relies heavily on embryonated chicken eggs, with very few studies producing NDV in cell culture. Here, NDV is produced in suspension Vero cells, and analytical assays (TCID
Identifiants
pubmed: 34835266
pii: vaccines9111335
doi: 10.3390/vaccines9111335
pmc: PMC8623276
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Canada Research Chairs
ID : CRC-240394
Organisme : National Research Council of Canada
ID : PR-013.1
Organisme : Mitacs
ID : Globalink Fellowship
Organisme : Fonds de Recherche du Québec - Santé
ID : Award
Références
Virol J. 2013 Nov 09;10:331
pubmed: 24209904
Vet Microbiol. 2019 Jan;228:53-60
pubmed: 30593380
Public Health. 2021 Sep;198:177-179
pubmed: 34461452
Sensors (Basel). 2012;12(9):12347-60
pubmed: 23112716
Oral Dis. 2021 May 15;:
pubmed: 33991381
Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4031-4033
pubmed: 28396427
Vaccine. 2010 May 7;28(21):3661-71
pubmed: 20347632
Curr Opin Immunol. 2021 Aug;71:111-116
pubmed: 34330017
J Virol Methods. 2008 Jun;150(1-2):63-9
pubmed: 18423899
Vaccine. 2019 Nov 8;37(47):6996-7002
pubmed: 31288997
Methods Mol Biol. 2020;2058:133-154
pubmed: 31486036
MMWR Morb Mortal Wkly Rep. 2021 Jun 11;70(23):858-864
pubmed: 34111059
Vet Immunol Immunopathol. 2016 Nov 15;181:59-67
pubmed: 27498407
Biomed Res Int. 2015;2015:504831
pubmed: 25815321
Vaccine. 2015 Nov 4;33(44):5974-81
pubmed: 26073013
Biotechnol Adv. 2020 Nov 15;44:107608
pubmed: 32768520
Biotechnol Bioeng. 2021 Jul;118(7):2649-2659
pubmed: 33837958
Acta Naturae. 2019 Jan-Mar;11(1):66-73
pubmed: 31024750
EBioMedicine. 2020 Dec;62:103132
pubmed: 33232870
iScience. 2021 Nov 19;24(11):103219
pubmed: 34632328
MethodsX. 2020 Feb 20;7:100806
pubmed: 32195130
Biotechnol J. 2015 May;10(5):728-40
pubmed: 25903999
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
J Pharm Sci. 2021 Feb;110(2):627-634
pubmed: 33242452
Virology. 2017 Feb;502:123-132
pubmed: 28039799
J Virol. 1995 Apr;69(4):2700-3
pubmed: 7884927
Appl Microbiol Biotechnol. 2010 Sep;88(2):461-75
pubmed: 20617311
J Gen Virol. 1977 Jul;36(1):59-74
pubmed: 886304
J Virol. 2005 Nov;79(21):13275-84
pubmed: 16227250
Int J Mol Sci. 2017 May 20;18(5):
pubmed: 28531117
Viruses. 2016 Jul 04;8(7):
pubmed: 27384578
Biotechnol Bioeng. 1998 Sep 5;59(5):567-75
pubmed: 10099373
Virol J. 2013 May 04;10:141
pubmed: 23642219
Curr Opin Immunol. 2021 Aug;71:27-33
pubmed: 33873076
NPJ Vaccines. 2021 Aug 20;6(1):106
pubmed: 34417462
Vet Microbiol. 2021 Oct;261:109181
pubmed: 34399297
Oncolytic Virother. 2017 Mar 03;6:21-30
pubmed: 28293547
Biosecur Bioterror. 2010 Dec;8(4):321-30
pubmed: 21043791